The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia

Autor: Ce, Canman, Ac, Wolff, Cy, Chen, Albert Fornace, Mb, Kastan

Publikováno v: Europe PubMed Central

The p53 protein is a critical participant in a signal transduction pathway which mediates a G1 cell cycle arrest and apoptotic cell death in mammalian cells after ionizing irradiation. Cells from patients with the cancer-prone, radiation-sensitive di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::a2436b6c8ffb4c8efc72307a0dc0448b
https://pubmed.ncbi.nlm.nih.gov/7923116

Medical informatics and the quality of health: new approaches to support patient care - findings from the IMIA Yearbook of Medical Informatics 2003

Autor: Ammenwerth E, Haux R, Kulikowski C, Bohne A, Brandner R, Brigl B, Fischer G, Garde S, Petra Knaup, Ruderich F, Schubert R, Singer R, Ac, Wolff

Publikováno v: Europe PubMed Central

The Yearbook of Medical Informatics is published annually by the International Medical Informatics Association (IMIA) and contains a selection of excellent papers on medical informatics research which have been recently published (http://www. yearboo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::896e033cf250f8eea6594d4f6e9c2ea0
http://europepmc.org/abstract/med/12743656

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Autor: Tarantino P; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Tayob N; Harvard Medical School, Boston, MA.; Division of Data Science, Dana-Farber Cancer Institute, Boston, MA., Villacampa G; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Oncology Data Science Vall d'Hebron Institute of Oncology, Barcelona, Spain., Dang C; Memorial Sloan Kettering Cancer Center, New York, NY., Yardley DA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN., Isakoff SJ; Harvard Medical School, Boston, MA.; Massachusetts General Hospital, Boston, MA., Valero V; MD Anderson Cancer Center, Houston, TX., Faggen M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Mulvey T; Harvard Medical School, Boston, MA.; Massachusetts General Hospital, Boston, MA., Bose R; Washington University School of Medicine, St Louis, MO., Weckstein D; New Hampshire Oncology Hematology, Manchester, NH., Wolff AC; Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC., Reeder-Hayes K; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Rugo HS; University of California, San Francisco, CA., Ramaswamy B; Ohio State University Comprehensive Cancer Center, Columbus, OH., Zuckerman D; St Luke's Mountain States Tumor Institute, Boise, ID., Hart L; Wake Forest Baptist Health, Winston-Salem, NC., Gadi VK; University of Illinois Cancer Center, Chicago, IL., Constantine M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Cheng K; North Shore-LIJ Cancer Institute, Lake Success, NY., Garrett AM; Northern Light Cancer Care, Brewer, ME., Marcom PK; Duke University School of Medicine, Durham, NC., Albain K; Loyola University Medical Center, Maywood, IL., DeFusco P; Hartford Healthcare Cancer Institute, Hartford, CT., Tung N; Harvard Medical School, Boston, MA.; Beth Israel Deaconess Medical Center, Boston, MA., Ardman B; Lowell General Hospital, Lowell, MA., Nanda R; UChicago Medicine, Chicago, IL., Jankowitz RC; Perelman Center for Advanced Medicine, Philadelphia, PA., Rimawi M; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Abramson V; Vanderbilt-Ingram Cancer Center, Nashville, TN., Pohlmann PR; MD Anderson Cancer Center, Houston, TX.; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC., Van Poznak C; Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Forero-Torres A; Kirklin UAB Hematology Oncology, Birmingham, AL., Liu MC; Natera, Inc, Austin, TX., Ruddy KJ; Mayo Clinic, Rochester, NY., Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., DeMeo M; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA., Burstein HJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Dell'Orto P; IEO European Institute of Oncology, IRCCS, Milan, Italy., Russo L; IEO European Institute of Oncology, IRCCS, Milan, Italy., Krause E; PathAI, Boston, MA., Newhouse DJ; NanoString Technologies, Inc, Boston, MA., Kurt BB; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA., Schneider B; Indiana University School of Medicine, Indianapolis, IN., Prat A; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain., Winer EP; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Yale Cancer Center, New Haven, CT., Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Yale Cancer Center, New Haven, CT., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Nov; Vol. 42 (31), pp. 3652-3665. Date of Electronic Publication: 2024 Jun 27.

Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer.

Autor: Kok M; Departments of Medical Oncology and Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Gielen RJ; Departments of Medical Oncology and Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Adams S; Perlmutter Cancer Center, NYU Langone Health, New York, NY.; Department of Medicine, NYU Grossman School of Medicine, Manhattan, NY., Lennerz JK; BostonGene, Waltham, MA., Sharma P; University of Kansas Medical Center, Westwood, KS., Loibl S; GBG Forschungs GmbH, Neu-Isenburg, Germany.; Centre for Haematology and Oncology, Bethanien, and Goethe University, Frankfurt, Germany., Reardon E; Physician, Patient., Sonke G; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Linn S; Departments of Medical Oncology and Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Delaloge S; Department of Cancer Medicine, Gustave Roussy, Villejuif, France., Lacombe D; European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium., Robinson T; Bristol Medical School, University of Bristol, Bristol, United Kingdom., Badve S; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Winship Cancer Institute, Atlanta, GA., Martin M; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain., Balko JM; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Ignatiadis M; Breast Medical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles, Bruxelles, Belgium., Curigliano G; European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy., Wolff AC; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Mittendorf EA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Loi S; Division of Cancer Research, Peter MacCallum Cancer Centre, Parkville, VIC, Australia.; The Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, VIC, Australia., Pusztai L; Department of Medicine, Yale Cancer Center, Yale University, New Haven, CT., Tolaney SM; Dana-Farber Cancer Institute, Boston, MA., Salgado R; Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium.; Division of Research, PeterMacCallum Cancer Centre, Melbourne, VIC, Australia.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Oct 20; Vol. 42 (30), pp. 3523-3529. Date of Electronic Publication: 2024 Jul 22.

Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast Cancer.

Autor: Thomas A; Duke Cancer Institute, Duke University, Durham, NC., Mayer EL; Dana-Farber Cancer Institute, Boston, MA., DeMichele A; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Harbeck N; Breast Center, Department of OB&GYN and CCC Munich, LMU University Hospital, Munich, Germany., Curigliano G; European Institute of Oncology, IRCCS, Milan, Italy., Ignatiadis M; Jules Bordet Institut, Hôpital Universitaire de Bruxelles, HUB, Brussels, Belgium., Adam V; Breast International Group, Brussels, Belgium., Zhou Y; Yale Cancer Center, Yale School of Medicine, New Haven, CT., Brown TP; University of Alabama at Birmingham, Birmingham, AL., Gilham L; Breast Cancer Trials (Australia & New Zealand), Melbourne, Australia., Chua BH; Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia., Kalinsky K; Winship Cancer Institute at Emory University, Atlanta, GA., Wolff AC; The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD., O'Reilly S; Cancer Trials Ireland, Dublin, Ireland.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Oct 09, pp. JCO2401080. Date of Electronic Publication: 2024 Oct 09.